Investors are hotly anticipating the US roll out of Futura Medical plc’s drug-free erectile dysfunction gel.
While they say that there has been “limited visibility” on plans since Haleon plc signed a $4m deal with Futura to commercialize MED3000 – branded as Eroxon in the UK and Europe – they suggest a 2024 launch is within the realms of possibility
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?